EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 25-Dec-2025 09:11 ET (25-Dec-2025 14:11 GMT/UTC)

Facility-based uptake of colorectal cancer screening in 45- to 49-year-olds after US guideline changes

JAMA Network
Peer-Reviewed Publication

The findings of this cohort study suggest that facility-based colorectal cancer screening among adults ages 45 to 49 increased nearly 10-fold following U.S. Preventive Services Task Force (USPSTF) guideline changes, far exceeding growth among those ages 50 to 75. This rapid adoption highlights early implementation by practitioners and patients. Although screening rates among adults ages 50 to 75 increased during the study period, the accelerated growth among those ages 45 to 49 reflected guideline integration into facility practices.

Journal: JAMA Network Open

Winners of the ASTRO-AstraZeneca small cell lung cancer therapy challenge announced

American Society for Radiation Oncology
Grant and Award Announcement

The American Society for Radiation Oncology (ASTRO) recently announced the three winning research proposals for the 2025 ASTRO-AstraZeneca Small Cell Lung Cancer (SCLC) Therapy Challenge, which supports research that will improve therapies and outcomes for patients with limited-stage SCLC through the integration of consolidation immunotherapy and emerging radiation therapy techniques.

As millions lag in colon cancer screening, new studies point to strategies to boost uptake and follow-up

Michigan Medicine - University of Michigan
Peer-Reviewed Publication

A pair of new studies examines two aspects of the colon cancer screening process: the preferences of patients and physicians for all currently available colorectal cancer screening options, and the impact of a 2023 federal policy change that eliminated out of pocket costs for those who get an abnormal result on a home-based stool test and then need a colonoscopy.

Journal: Current Medical Research and Opinion
Funder: Exact Sciences Corporation

Wake Forest University School of Medicine scientists uncover cancer treatment strategy that pushes tumor cells past their breaking point

Atrium Health Wake Forest Baptist
Peer-Reviewed Publication

Researchers have uncovered a promising cancer treatment strategy by targeting a mitochondrial protein called peroxiredoxin-3 (PRX3). PRX3 normally acts as a cleanup system inside cancer cells, breaking down hydrogen peroxide before it becomes toxic. The team discovered a compound fragment that binds to PRX3 and switches it off, causing hydrogen peroxide to accumulate beyond the cell’s tolerance. This surge in oxidative stress overwhelms cancer cells, while sparing healthy ones, offering a novel approach to therapy that flips the traditional model of reducing stress into one that exploits cancer’s vulnerability.

Journal: Science Advances
Funder: Wake Forest Innovations Catalyst Fund, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Center for Redox Biology and Medicine.

NCCN celebrates expanding access to cancer treatment in Africa at 2025 AORTIC Meeting with new NCCN adaptations for Sub-Saharan Africa

National Comprehensive Cancer Network
Business Announcement

As part of the 2025 AORTIC Meeting, the African Cancer Coalition, American Cancer Society, and NCCN showcased the transition from harmonized clinical practice guidelines to the new International Adaptations of NCCN Guidelines for Sub-Saharan Africa, representing how much progress has been made in cancer care access across the region.

RTOG Foundation opens new study testing [177Lu]Lu-DOTA-TATE for adults with meningioma

RTOG Foundation
Business Announcement

RTOG Foundation, a non-profit organization which conducts clinical trials designed to discover more effective cancer therapies, recently opened a new trial RTOG 3523, also known as the “MOMENTUM-1” study, testing the radioactive drug [¹⁷⁷Lu]Lu-DOTA-TATE (hereafter referred to as ¹⁷⁷Lu-Dotatate) in adult who have progressive intracranial grade 1-3 meningioma.

Study confirms sustained reduction in prostate cancer mortality with PSA screening

Tampere University
Peer-Reviewed Publication

A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific antigen (PSA) screening. However, the findings also highlight the issue of overdiagnosis, or the detection of slow-growing cancers that are unlikely to affect a patient’s lifespan, associated with PSA screening. To address this concern, the researchers advocate the development of risk-based screening.

Journal: New England Journal of Medicine

Scanning nanoprobe microscope reveals the hidden flexibility of cancer cells

Nano Life Science Institute (NanoLSI), Kanazawa University
Peer-Reviewed Publication

Researchers at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, report in ACS Applied Nano Materials a new method to precisely measure nuclear elasticity—the stiffness or softness of the cell nucleus—in living cells. By employing a technique called Nanoendoscopy-AFM (NE-AFM), which inserts a nanoneedle probe directly into cells, the team revealed how cancer cell nuclei stiffen or soften depending on chromatin structure and environmental conditions.

The findings provide fundamental insights into how the physical properties of cancer cell nuclei change during disease progression, highlighting their potential as biomarkers for diagnosis and treatment evaluation.

Journal: ACS Applied Nano Materials

New survey reveals men would rather sit in traffic than talk about prostate health

Orlando Health
Reports and Proceedings

A new survey from Orlando Health reveals that over one-third of men (38%) would rather endure stressful situations, such as watching their team lose a big game or being stuck in traffic, than discuss their prostate health. This widespread reluctance to address a common health issue often leads to delayed diagnosis and treatment for conditions like an enlarged prostate.

New nanoparticle therapy shrinks pancreatic tumors and extends survival in preclinical study

University of Miami Miller School of Medicine
Peer-Reviewed Publication

A new study has found for the first time that magnetoelectric nanoparticles — tiny, wirelessly controlled particles activated by magnetic fields — can both locate and destroy pancreatic tumors in preclinical models, offering a potential new approach to minimally invasively treating one of the deadliest cancers.

Journal: Advanced Science

57
58
59
60
61